Acute Lymphoblastic Leukaemia / Lymphoblastic Lymphoma B014

Current RMA Instruments
Reasonable Hypothesis SOP
33 of 2021
Balance of Probabilities SOP
34 of 2021
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 204.0
  • ICD-10-AM Codes: C91.0
Brief description

This is a cancer of immature white blood cells (lymphoblasts).  There are two overlapping clinical presentations of the same disease - leukaemia, when bone marrow blast cells predominate, and lymphoma, when a mass lesion in the mediastinum or elsewhere is the predominant feature.

Confirming the diagnosis

Diagnosis is usually suspected based on a finding of swollen lymph nodes or a blood test showing abnormal white cells.  A bone marrow biopsy is required to confirm the diagnosis and differentiate the condition from other diseases.

The relevant medical specialist is a haematologist.

Diagnoses covered by SOP
  • acute lymphoid leukaemia
  • acute lymphocytic leukaemia
  • B-lymphoblastic leukemia/lymphoma (B-ALL/LBL)
  • T-lymphoblastic leukemia/lymphoma (T-ALL/LBL)
  • lymphoblastic lymphoma
Conditions excluded from SOP
  • acute myeloid leukaemia*
  • acute undifferentiated leukaemia#
  • adult T-cell leukaemia/lymphoma* (non-Hodgkin lymphoma SOP)
  • Burkitt’s lymphoma/leukaemia* (non-Hodgkin lymphoma SOP)
  • chronic lymphoid leukaemia*
  • chronic myeloid leukaemia*
  • indolent T-lymphoblastic proliferation#
  • non-Hodgkin lymphoma*

* another SOP applies

# non-SOP condition

Clinical onset

Clinical onset will be when the diagnosis was confirmed, or shortly before that time if characteristic symptoms were present, such as easy bruising/bleeding, recurrent infections or symptoms from anaemia. 75% of cases occur in children under 6, but there is a second peak in adults > 60 years old.

Clinical worsening

The only worsening factor is for inability to obtain appropriate clinical management.  The prognosis in adults is generally poor.  Worsening beyond the normal progression of the disease will be difficult to establish and will require specialist opinion.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/sops-grouped-icd-body-system/b/acute-lymphoblastic-leukaemia-b014-c910-c915

Last amended

Rulebase for acute lymphoid leukaemia

<h5>Current RMA Instruments</h5><table border="1" cellspacing="1" cellpadding="1"><tbody><tr><td><address><a href="http://www.rma.gov.au/assets/SOP/2021/eae501d9e8/033.pdf&quot; target="_blank">Reasonable Hypothesis SOP</a></address></td><td>33 of 2021</td></tr><tr><td><address><a href="http://www.rma.gov.au/assets/SOP/2021/705c092af2/034.pdf&quot; target="_blank">Balance of Probabilities SOP</a></address></td><td>34 of 2021</td></tr></tbody></table><h5>Changes from previous Instruments</h5><p><drupal-media data-entity-type="media" data-entity-uuid="65e99c24-8c40-472e-88ae-cb011637fc39" data-view-mode="wysiwyg"></drupal-media></p><h5>ICD Coding</h5><ul><li>ICD-9-CM Codes: 204.0</li><li>ICD-10-AM Codes: C91.0</li></ul><h5>Brief description</h5><p>This is a cancer of immature white blood cells (lymphoblasts).  There are two overlapping clinical presentations of the same disease - leukaemia, when bone marrow blast cells predominate, and lymphoma, when a mass lesion in the mediastinum or elsewhere is the predominant feature.</p><h5>Confirming the diagnosis</h5><p>Diagnosis is usually suspected based on a finding of swollen lymph nodes or a blood test showing abnormal white cells.  A bone marrow biopsy is required to confirm the diagnosis and differentiate the condition from other diseases.</p><p>The relevant medical specialist is a haematologist.</p><h5>Diagnoses covered by SOP</h5><ul><li>acute lymphoid leukaemia</li><li>acute lymphocytic leukaemia</li><li>B-lymphoblastic leukemia/lymphoma (B-ALL/LBL)</li><li>T-lymphoblastic leukemia/lymphoma (T-ALL/LBL)</li><li>lymphoblastic lymphoma</li></ul><h5><b>Conditions excluded from SOP</b></h5><ul><li>acute myeloid leukaemia*</li><li>acute undifferentiated leukaemia<span><sup>#</sup></span></li><li>adult T-cell leukaemia/lymphoma* (non-Hodgkin lymphoma SOP)</li><li>Burkitt’s lymphoma/leukaemia* (non-Hodgkin lymphoma SOP)</li><li>chronic lymphoid leukaemia*</li><li>chronic myeloid leukaemia*</li><li>indolent T-lymphoblastic proliferation<span><sup>#</sup></span></li><li>non-Hodgkin lymphoma*</li></ul><p>* another SOP applies</p><p><span><sup>#</sup></span> non-SOP condition</p><h5><b>Clinical onset</b></h5><p>Clinical onset will be when the diagnosis was confirmed, or shortly before that time if characteristic symptoms were present, such as easy bruising/bleeding, recurrent infections or symptoms from anaemia. 75% of cases occur in children under 6, but there is a second peak in adults &gt; 60 years old.</p><h5>Clinical worsening</h5><p>The only worsening factor is for inability to obtain appropriate clinical management.  The prognosis in adults is generally poor.  Worsening beyond the normal progression of the disease will be difficult to establish and will require specialist opinion.</p>

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-lymphoblastic-leukaemia-b014-c910-c915/rulebase-acute-lymphoid-leukaemia

A course of therapeutic radiation

Current RMA Instruments
Reasonable Hypothesis SOP
33 of 2021
Balance of Probabilities SOP
34 of 2021
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 204.0
  • ICD-10-AM Codes: C91.0
Brief description

This is a cancer of immature white blood cells (lymphoblasts).  There are two overlapping clinical presentations of the same disease - leukaemia, when bone marrow blast cells predominate, and lymphoma, when a mass lesion in the mediastinum or elsewhere is the predominant feature.

Confirming the diagnosis

Diagnosis is usually suspected based on a finding of swollen lymph nodes or a blood test showing abnormal white cells.  A bone marrow biopsy is required to confirm the diagnosis and differentiate the condition from other diseases.

The relevant medical specialist is a haematologist.

Diagnoses covered by SOP
  • acute lymphoid leukaemia
  • acute lymphocytic leukaemia
  • B-lymphoblastic leukemia/lymphoma (B-ALL/LBL)
  • T-lymphoblastic leukemia/lymphoma (T-ALL/LBL)
  • lymphoblastic lymphoma
Conditions excluded from SOP
  • acute myeloid leukaemia*
  • acute undifferentiated leukaemia#
  • adult T-cell leukaemia/lymphoma* (non-Hodgkin lymphoma SOP)
  • Burkitt’s lymphoma/leukaemia* (non-Hodgkin lymphoma SOP)
  • chronic lymphoid leukaemia*
  • chronic myeloid leukaemia*
  • indolent T-lymphoblastic proliferation#
  • non-Hodgkin lymphoma*

* another SOP applies

# non-SOP condition

Clinical onset

Clinical onset will be when the diagnosis was confirmed, or shortly before that time if characteristic symptoms were present, such as easy bruising/bleeding, recurrent infections or symptoms from anaemia. 75% of cases occur in children under 6, but there is a second peak in adults > 60 years old.

Clinical worsening

The only worsening factor is for inability to obtain appropriate clinical management.  The prognosis in adults is generally poor.  Worsening beyond the normal progression of the disease will be difficult to establish and will require specialist opinion.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-lymphoblastic-leukaemia-b014-c910-c915/rulebase-acute-lymphoid-leukaemia/course-therapeutic-radiation

Atomic radiation

Current RMA Instruments
Reasonable Hypothesis SOP
33 of 2021
Balance of Probabilities SOP
34 of 2021
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 204.0
  • ICD-10-AM Codes: C91.0
Brief description

This is a cancer of immature white blood cells (lymphoblasts).  There are two overlapping clinical presentations of the same disease - leukaemia, when bone marrow blast cells predominate, and lymphoma, when a mass lesion in the mediastinum or elsewhere is the predominant feature.

Confirming the diagnosis

Diagnosis is usually suspected based on a finding of swollen lymph nodes or a blood test showing abnormal white cells.  A bone marrow biopsy is required to confirm the diagnosis and differentiate the condition from other diseases.

The relevant medical specialist is a haematologist.

Diagnoses covered by SOP
  • acute lymphoid leukaemia
  • acute lymphocytic leukaemia
  • B-lymphoblastic leukemia/lymphoma (B-ALL/LBL)
  • T-lymphoblastic leukemia/lymphoma (T-ALL/LBL)
  • lymphoblastic lymphoma
Conditions excluded from SOP
  • acute myeloid leukaemia*
  • acute undifferentiated leukaemia#
  • adult T-cell leukaemia/lymphoma* (non-Hodgkin lymphoma SOP)
  • Burkitt’s lymphoma/leukaemia* (non-Hodgkin lymphoma SOP)
  • chronic lymphoid leukaemia*
  • chronic myeloid leukaemia*
  • indolent T-lymphoblastic proliferation#
  • non-Hodgkin lymphoma*

* another SOP applies

# non-SOP condition

Clinical onset

Clinical onset will be when the diagnosis was confirmed, or shortly before that time if characteristic symptoms were present, such as easy bruising/bleeding, recurrent infections or symptoms from anaemia. 75% of cases occur in children under 6, but there is a second peak in adults > 60 years old.

Clinical worsening

The only worsening factor is for inability to obtain appropriate clinical management.  The prognosis in adults is generally poor.  Worsening beyond the normal progression of the disease will be difficult to establish and will require specialist opinion.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-lymphoblastic-leukaemia-b014-c910-c915/rulebase-acute-lymphoid-leukaemia/atomic-radiation

HTLV-1 infection

Current RMA Instruments
Reasonable Hypothesis SOP
33 of 2021
Balance of Probabilities SOP
34 of 2021
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 204.0
  • ICD-10-AM Codes: C91.0
Brief description

This is a cancer of immature white blood cells (lymphoblasts).  There are two overlapping clinical presentations of the same disease - leukaemia, when bone marrow blast cells predominate, and lymphoma, when a mass lesion in the mediastinum or elsewhere is the predominant feature.

Confirming the diagnosis

Diagnosis is usually suspected based on a finding of swollen lymph nodes or a blood test showing abnormal white cells.  A bone marrow biopsy is required to confirm the diagnosis and differentiate the condition from other diseases.

The relevant medical specialist is a haematologist.

Diagnoses covered by SOP
  • acute lymphoid leukaemia
  • acute lymphocytic leukaemia
  • B-lymphoblastic leukemia/lymphoma (B-ALL/LBL)
  • T-lymphoblastic leukemia/lymphoma (T-ALL/LBL)
  • lymphoblastic lymphoma
Conditions excluded from SOP
  • acute myeloid leukaemia*
  • acute undifferentiated leukaemia#
  • adult T-cell leukaemia/lymphoma* (non-Hodgkin lymphoma SOP)
  • Burkitt’s lymphoma/leukaemia* (non-Hodgkin lymphoma SOP)
  • chronic lymphoid leukaemia*
  • chronic myeloid leukaemia*
  • indolent T-lymphoblastic proliferation#
  • non-Hodgkin lymphoma*

* another SOP applies

# non-SOP condition

Clinical onset

Clinical onset will be when the diagnosis was confirmed, or shortly before that time if characteristic symptoms were present, such as easy bruising/bleeding, recurrent infections or symptoms from anaemia. 75% of cases occur in children under 6, but there is a second peak in adults > 60 years old.

Clinical worsening

The only worsening factor is for inability to obtain appropriate clinical management.  The prognosis in adults is generally poor.  Worsening beyond the normal progression of the disease will be difficult to establish and will require specialist opinion.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-lymphoblastic-leukaemia-b014-c910-c915/rulebase-acute-lymphoid-leukaemia/htlv-1-infection

Inability to obtain appropriate clinical management for acute lymphoid leukaemia

Current RMA Instruments
Reasonable Hypothesis SOP
33 of 2021
Balance of Probabilities SOP
34 of 2021
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 204.0
  • ICD-10-AM Codes: C91.0
Brief description

This is a cancer of immature white blood cells (lymphoblasts).  There are two overlapping clinical presentations of the same disease - leukaemia, when bone marrow blast cells predominate, and lymphoma, when a mass lesion in the mediastinum or elsewhere is the predominant feature.

Confirming the diagnosis

Diagnosis is usually suspected based on a finding of swollen lymph nodes or a blood test showing abnormal white cells.  A bone marrow biopsy is required to confirm the diagnosis and differentiate the condition from other diseases.

The relevant medical specialist is a haematologist.

Diagnoses covered by SOP
  • acute lymphoid leukaemia
  • acute lymphocytic leukaemia
  • B-lymphoblastic leukemia/lymphoma (B-ALL/LBL)
  • T-lymphoblastic leukemia/lymphoma (T-ALL/LBL)
  • lymphoblastic lymphoma
Conditions excluded from SOP
  • acute myeloid leukaemia*
  • acute undifferentiated leukaemia#
  • adult T-cell leukaemia/lymphoma* (non-Hodgkin lymphoma SOP)
  • Burkitt’s lymphoma/leukaemia* (non-Hodgkin lymphoma SOP)
  • chronic lymphoid leukaemia*
  • chronic myeloid leukaemia*
  • indolent T-lymphoblastic proliferation#
  • non-Hodgkin lymphoma*

* another SOP applies

# non-SOP condition

Clinical onset

Clinical onset will be when the diagnosis was confirmed, or shortly before that time if characteristic symptoms were present, such as easy bruising/bleeding, recurrent infections or symptoms from anaemia. 75% of cases occur in children under 6, but there is a second peak in adults > 60 years old.

Clinical worsening

The only worsening factor is for inability to obtain appropriate clinical management.  The prognosis in adults is generally poor.  Worsening beyond the normal progression of the disease will be difficult to establish and will require specialist opinion.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-lymphoblastic-leukaemia-b014-c910-c915/rulebase-acute-lymphoid-leukaemia/inability-obtain-appropriate-clinical-management-acute-lymphoid-leukaemia

Infection with the Epstein-Barr virus

Current RMA Instruments
Reasonable Hypothesis SOP
33 of 2021
Balance of Probabilities SOP
34 of 2021
Changes from previous Instruments

ICD Coding
  • ICD-9-CM Codes: 204.0
  • ICD-10-AM Codes: C91.0
Brief description

This is a cancer of immature white blood cells (lymphoblasts).  There are two overlapping clinical presentations of the same disease - leukaemia, when bone marrow blast cells predominate, and lymphoma, when a mass lesion in the mediastinum or elsewhere is the predominant feature.

Confirming the diagnosis

Diagnosis is usually suspected based on a finding of swollen lymph nodes or a blood test showing abnormal white cells.  A bone marrow biopsy is required to confirm the diagnosis and differentiate the condition from other diseases.

The relevant medical specialist is a haematologist.

Diagnoses covered by SOP
  • acute lymphoid leukaemia
  • acute lymphocytic leukaemia
  • B-lymphoblastic leukemia/lymphoma (B-ALL/LBL)
  • T-lymphoblastic leukemia/lymphoma (T-ALL/LBL)
  • lymphoblastic lymphoma
Conditions excluded from SOP
  • acute myeloid leukaemia*
  • acute undifferentiated leukaemia#
  • adult T-cell leukaemia/lymphoma* (non-Hodgkin lymphoma SOP)
  • Burkitt’s lymphoma/leukaemia* (non-Hodgkin lymphoma SOP)
  • chronic lymphoid leukaemia*
  • chronic myeloid leukaemia*
  • indolent T-lymphoblastic proliferation#
  • non-Hodgkin lymphoma*

* another SOP applies

# non-SOP condition

Clinical onset

Clinical onset will be when the diagnosis was confirmed, or shortly before that time if characteristic symptoms were present, such as easy bruising/bleeding, recurrent infections or symptoms from anaemia. 75% of cases occur in children under 6, but there is a second peak in adults > 60 years old.

Clinical worsening

The only worsening factor is for inability to obtain appropriate clinical management.  The prognosis in adults is generally poor.  Worsening beyond the normal progression of the disease will be difficult to establish and will require specialist opinion.

Source URL: https://clik.dva.gov.au/ccps-medical-research-library/statements-principles/b/acute-lymphoblastic-leukaemia-b014-c910-c915/rulebase-acute-lymphoid-leukaemia/infection-epstein-barr-virus